evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

189 questions · 190 findings · 12 reviews · Eyes and Vision

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 57 · 30%GRADE not reported 4 · 2.1%Very low 53 · 27.9%Low 33 · 17.4%Moderate 28 · 14.7%High 15 · 7.9%

Summary of findings 3: Efficacy and safety of IVT pegcetacoplan 4‐weekly (monthly) vs sham

Safety: Development of macular neovascularisation or exudative AMD at 1 year · adults with GA due to AMD

Summary of findings 3: Efficacy and safety of IVT pegcetacoplan… showed no clear difference in safety: Development of macular neovascularisation or exudative AMD… compared with sham; GRADE not reported.

1 finding from 1 review

Summary of findings 3: Efficacy and safety of IVT pegcetacoplan 4‐weekly (monthly) vs sham

Safety: Development of endophthalmitis at 1 year · adults with GA due to AMD

Summary of findings 3: Efficacy and safety of IVT pegcetacoplan… showed no clear difference in safety: Development of endophthalmitis at 1 year compared with sham (moderate certainty).

1 finding from 1 review

Summary of findings 4: Efficacy and safety of IVT pegcetacoplan 8‐weekly (every other month) vs sham

Change in visual acuity (logMAR) ‐ 12 months (negative is better) · adults with GA due to AMD

Summary of findings 4: Efficacy and safety of IVT pegcetacoplan… showed no clear difference in change in BCVA from baseline at 1 year (ETDRS letters) compared with sham (moderate certainty).

1 finding from 1 review

Summary of findings 4: Efficacy and safety of IVT pegcetacoplan 8‐weekly (every other month) vs sham

Safety: Development of macular neovascularisation or exudative AMD at 1 year · adults with GA due to AMD

Summary of findings 4: Efficacy and safety of IVT pegcetacoplan… showed no clear difference in safety: Development of macular neovascularisation or exudative AMD… compared with sham; GRADE not reported.

1 finding from 1 review

Summary of findings 4: Efficacy and safety of IVT pegcetacoplan 8‐weekly (every other month) vs sham

Safety: Development of endophthalmitis at 1 year · adults with GA due to AMD

Summary of findings 4: Efficacy and safety of IVT pegcetacoplan… showed no clear difference in safety: Development of endophthalmitis at 1 year compared with sham (moderate certainty).

1 finding from 1 review

Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to 8‐weekly (every other month) vs sham

Safety: Development of macular neovascularisation or exudative AMD at 1 year · adults with GA due to AMD

Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to… showed no clear difference in safety: Development of macular neovascularisation or exudative AMD… compared with sham (low certainty).

1 finding from 1 review

Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to 8‐weekly (every other month) vs sham

Safety: Development of endophthalmitis at 1 year · adults with GA due to AMD

Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to… showed no clear difference in safety: Development of endophthalmitis at 1 year compared with sham (moderate certainty).

1 finding from 1 review

Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to 8‐weekly (every other month) vs sham

Loss of ≥ 15 letters BCVA at 1 year · adults with GA due to AMD

Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to… showed no clear difference in loss of ≥ 15 letters BCVA at 1 year compared with sham (moderate certainty).

1 finding from 1 review